Article
iNIZIO
Professional Medical Writer Assistance in Oncology Clinical Trials
Summary
- The use of professional medical writers (PMWs) in oncologic phase III randomized controlled trials (RCTs) has been historically low, but recent data on their usage is limited.
- This study aimed to quantify the usage of PMWs in cancer-specific phase III RCTs by analyzing trial manuscripts on ClinicalTrials.gov.
- Out of 600 trials, 260 (43.3%) involved PMWs in writing the trial manuscript.
- Industry-funded trials were significantly more likely to use PMWs compared to nonindustry trials (54.9% vs. 3.0%, p < .001).
- PMW usage was higher in trials that met their primary endpoint (53.4% vs. 32.9%, p < .001) and those resulting in FDA approval (63.1% vs. 36.3%, p < .001).
- Among treatment interventions, PMW use was most prevalent in systemic therapy trials (50.2%).
- The study observed a significant increase in the use of PMWs over time (odds ratio: 1.11/year, p = .001).
- The study calls for increased transparency in reporting the funding and use of PMWs.
Academic publishing remains the cornerstone of cancer research and scientific communication of clinical trials. Over the years, there has been increasing interest in the use of professional medical writers (PMWs) to help investigators improve quality of writing and/or reduce the time to publication. Use rates of such PMW services have historically been low, but contemporary data regarding PMW usage remain scarce. With an increasing role of industry sponsorship in cancer clinical trials, we sought to characterize the rate of PMW use among reports of phase III cancer clinical trial results, focusing on factors associated with PMW usage.
PMW usage, phase III oncology trials, professional medical writer assistance
Related Topics
You May Also Like
iNIZIO
Article
Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Article
Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
Article
Sarah A. Weiss, MD, and Harriet Kluger, MD
CheckMate-067: Raising the Bar for the Next Decade in Oncology
Article
Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
Article
Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma